Pharma Focus Europe
ThermoFisher Scientific - Custom and Bulks

Utilizing Turbine and Harmonic Discovery Pair Simulation Alongside Expertise in Multi-Target Kinase Inhibition Chemistry for the Development of a Novel Cancer Therapy

Monday, April 01, 2024

Turbine, a company pioneering the development of the world's first predictive simulation of patient biology, and Harmonic Discovery (Harmonic), a therapeutics company specializing in kinase drug discovery and targeted polypharmacology, have announced a collaboration. Their aim is to co-develop novel cancer therapies targeting a dark kinase identified for its significance in cancer dependency using Turbine’s Simulated Cell™ platform.

According to Daniel Veres, M.D., Ph.D., Chief Scientific Officer and Co-Founder of Turbine, the dark kinase NEK1 shows promising potential as a drug target for developing cancer therapies to tackle resistance challenges in clinical settings. Veres emphasized the value of combining Harmonic's expertise in multi-specific kinase-targeted drug design with Turbine's unique ability to guide drug discovery through simulated experiments and causal interpretation in a vast biological search space.

Rayees Rahman, Ph.D., CEO and Co-Founder of Harmonic Discovery, highlighted their integrated kinase drug discovery platform, aiming to revolutionize current drug discovery paradigms. Rahman expressed confidence in integrating Turbine's biological simulation technology with their approach, anticipating a more effective strategy for selecting and advancing kinase-targeted therapies in oncology.

The collaboration involves Turbine’s simulations informing Harmonic’s generative chemistry models to develop new kinase inhibitor therapies. Harmonic will oversee computational chemistry and medicinal chemistry activities, while Turbine will conduct in silico simulations and wet-lab validation of target biology. This includes identifying synergistic kinase co-targets to NEK1 and determining patient populations most likely to benefit from the therapies. Financial details of the collaboration were not disclosed.

 

Source: businesswire.com

magazine-slider-img
Get instant
access to our latest e-book
patheon - Mastering API production at every scaleLab Indonesia 20247th Pharma Packaging and Labelling Forum 2024Future Labs Live - 2024World Orphan Drug Congress 2024World Vaccine Congress Europe 2024Sartorius Webinar - Pave Your Weigh to Accurate Analytical ResultsEUROPEAN PHARMA OUTSOURCING SUMMIT 2024patheon - Revolutionizing PharmaWorld Vaccine Congress Europe 2024